|
|
|
Volumn 6, Issue 4, 2008, Pages
|
|
Lenalidomide in myelodysplastic syndromes
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZACITIDINE;
CC 11006;
ERYTHROPOIETIN;
ERYTHROPOIETIN RECEPTOR;
IMATINIB;
IMMUNOMODULATING AGENT;
LENALIDOMIDE;
POMALIDOMIDE;
RECOMBINANT ERYTHROPOIETIN;
THALIDOMIDE;
UNCLASSIFIED DRUG;
DRUG DERIVATIVE;
IMMUNOLOGIC FACTOR;
ACUTE GRANULOCYTIC LEUKEMIA;
BLOOD TRANSFUSION;
BONE MARROW SUPPRESSION;
CHROMOSOME 5Q;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
CYTOTOXICITY;
DRUG ACTIVITY;
DRUG APPROVAL;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG POTENCY;
DRUG SAFETY;
ERYTHROPOIESIS;
FOLLOW UP;
GENE DELETION;
HEMATOPOIESIS;
HUMAN;
IMMUNOMODULATION;
MULTIPLE MYELOMA;
MYELODYSPLASTIC SYNDROME;
NEUTROPENIA;
NOTE;
SIGNAL TRANSDUCTION;
THROMBOCYTOPENIA;
ARTICLE;
GENETICS;
REMISSION;
CLINICAL TRIALS AS TOPIC;
GENE DELETION;
HUMANS;
IMMUNOLOGIC FACTORS;
MYELODYSPLASTIC SYNDROMES;
REMISSION INDUCTION;
THALIDOMIDE;
|
|
EID: 46449108625
PISSN: 15430790
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
